Three years down, many more to go.

Following the first stretch of what has so far been a successful partnership between Pfizer and CytoReason, the duo has opted to extend their collaboration and continue their work to apply CytoReason’s artificial intelligence technology to Pfizer’s drug development efforts.

Read more here.